diff --git a/src/contents/Home.tsx b/src/contents/Home.tsx index fe956527a7efe226258e6b5a3bd4c6a5ad89cb16..dedbd8737c4a82fbe3ceac7227ef11d5256ae4db 100644 --- a/src/contents/Home.tsx +++ b/src/contents/Home.tsx @@ -100,6 +100,21 @@ export function Home() { <FadeIn filepath="https://static.igem.wiki/teams/5247/landing-page/lp-6-2.svg" bg='https://static.igem.wiki/teams/5247/landing-page/lp-6-2.svg'></FadeIn> <FadeIn filepath="https://static.igem.wiki/teams/5247/landing-page/lp-7-2.svg" bg='https://static.igem.wiki/teams/5247/landing-page/lp-7-2.svg'></FadeIn> <FadeIn filepath="https://static.igem.wiki/teams/5247/landing-page/lp-8-2.svg" bg='https://static.igem.wiki/teams/5247/landing-page/lp-8-2.svg'></FadeIn> + <FadeIn filepath="https://static.igem.wiki/teams/5247/landing-page/lp-9-2.svg" bg='https://static.igem.wiki/teams/5247/landing-page/lp-9-2.svg'></FadeIn> + <FadeIn filepath="https://static.igem.wiki/teams/5247/landing-page/lp-10.svg" bg='https://static.igem.wiki/teams/5247/landing-page/lp-10.svg'></FadeIn> + <FadeIn filepath="https://static.igem.wiki/teams/5247/landing-page/lp-11-2.svg" bg='https://static.igem.wiki/teams/5247/landing-page/lp-11-2.svg'></FadeIn> + <FadeIn filepath="https://static.igem.wiki/teams/5247/landing-page/lp-12.webp" bg='https://static.igem.wiki/teams/5247/landing-page/lp-12.webp'></FadeIn> + <FadeIn filepath="https://static.igem.wiki/teams/5247/landing-page/lp-13-2.webp" bg='https://static.igem.wiki/teams/5247/landing-page/lp-13-2.webp'></FadeIn> + <FadeIn filepath="https://static.igem.wiki/teams/5247/landing-page/lp-14.webp" bg='https://static.igem.wiki/teams/5247/landing-page/lp-14.webp'></FadeIn> + <FadeIn filepath="https://static.igem.wiki/teams/5247/landing-page/lp-15.webp" bg='https://static.igem.wiki/teams/5247/landing-page/lp-15.webp'></FadeIn> + <FadeIn filepath="https://static.igem.wiki/teams/5247/landing-page/lp-16.webp" bg='https://static.igem.wiki/teams/5247/landing-page/lp-16.webp'></FadeIn> + <FadeIn filepath="https://static.igem.wiki/teams/5247/landing-page/lp-17.svg" bg='https://static.igem.wiki/teams/5247/landing-page/lp-17.svg'></FadeIn> + <FadeIn filepath="https://static.igem.wiki/teams/5247/landing-page/lp-18-2.svg" bg='https://static.igem.wiki/teams/5247/landing-page/lp-18-2.svg'></FadeIn> + <FadeIn filepath="https://static.igem.wiki/teams/5247/landing-page/lp-19-2.svg" bg='https://static.igem.wiki/teams/5247/landing-page/lp-19-2.svg'></FadeIn> + + + + diff --git a/src/contents/description.tsx b/src/contents/description.tsx index 1202bb2413622005ebe5cf1b961a75b1cb97ca0e..0ea789cc17f1153d331e74535c25ab36b05c5e70 100644 --- a/src/contents/description.tsx +++ b/src/contents/description.tsx @@ -24,7 +24,16 @@ export function Description() { <div className="row mt-4"> <div className="col"> <Section title="Abstract" id="Abstract"> - <p id="obenindescription" >We are proud to introduce <PreCyse/>, our next-generation Prime Editing technology aimed at developing an innovative gene therapy for cystic fibrosis, specifically targeting the most common mutation, <b>F508del</b> of the CFTR gene. PreCyse is designed to address key limitations in current treatments, including limited size, speed, precision, and long-term effectiveness. Our approach integrates <b>PrimeGuide</b>, a highly optimized Prime Editing system, with <b>AirBuddy</b>, a novel lipid nanoparticle (LNP) delivery platform. The <b>SORT LNPs</b> used in AirBuddy are optimized for pulmonary delivery, offering precise organ targeting and structural stability throughout the inhalation process. As a Postdoc at the Broad Institute of MIT and Havard—where Prime Editing was first pioneered—observed, “<i>Everyone is looking for smaller prime editors</i>†and PrimeGuide embodies this vision by utilizing a smaller, more efficient editing complex. Unlike current treatments, which often require frequent administration and provide only temporary relief, PreCyse is developed as a monthly applied therapy with the potential for longer-lasting results, reducing the frequency of use and improving patient outcomes. By lowering costs and improving accessibility, PreCyse aims to offer a more advanced and user-friendly cure for cystic fibrosis. </p> + <p id="obenindescription">We are proud to present <PreCyse/>, a next-generation Prime Editing technology, as innovative gene therapy approach for cystic fibrosis + specifically targeting the most common mutation <b>F508del</b> of the CFTR gene. Cystic fibrosis is a severe disorder that primarily affects the lungs + and for which only short-term symptomatic treatments exist. PreCyse aims to provide long-term relief by delivering a small genetic payload with speed + and precision. Our approach integrates <b>PrimeGuide</b>, a highly optimized Prime Editing system, with <b>AirBuddy</b>, a novel lipid nanoparticle + (LNP) delivery platform. The <b>SORT LNPs</b> used in AirBuddy are optimized for pulmonary delivery, offering precise organ targeting and structural + stability throughout the inhalation process. Small payload size is key for effective delivery and compatibility with viral vectors, which have a + limited capacity. PrimeGuide embodies this vision by utilizing a smaller, more efficient editing complex. Current treatments often require daily + administration whereas PreCyse is currently developed as a monthly applied therapy. In addition, Prime Editing holds the promise to offer a causal cure, + when mutations are corrected in stem cells. Our approach aims to reduce medication frequency while improving patient outcomes. + By lowering costs and improving accessibility, PreCyse aspires to offer an advanced and user-friendly cure for cystic fibrosis.</p> </Section> <Section title="Our Motivation" id="Our Motivation"> <div className="row align-items-center">